Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.

Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC50s of 223 and 509 nM, respectively.

Aldometanib (LXY-05-029) is a selective inhibitor of aldolase (ALDOA) with an IC50 of 50 uM in in vitro enzymatic assays. It also activates lysosomal AMPK by blocking FBP-aldolase binding, mimicking glucose starvation and improving metabolic health without causing hypoglycemia.

Aldometanib (LXY-05-029) is a selective inhibitor of aldolase (ALDOA) with an IC50 of 50 uM in in vitro enzymatic assays. It also activates lysosomal AMPK by blocking FBP-aldolase binding, mimicking glucose starvation and improving metabolic health without causing hypoglycemia.

Aldometanib (LXY-05-029) is a selective inhibitor of aldolase (ALDOA) with an IC50 of 50 uM in in vitro enzymatic assays. It also activates lysosomal AMPK by blocking FBP-aldolase binding, mimicking glucose starvation and improving metabolic health without causing hypoglycemia.

Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.

Aldometanib (LXY-05-029) is a selective inhibitor of aldolase (ALDOA) with an IC50 of 50 uM in in vitro enzymatic assays. It also activates lysosomal AMPK by blocking FBP-aldolase binding, mimicking glucose starvation and improving metabolic health without causing hypoglycemia.